PBR Nachrichten

 

The therapy is indicated to improve functional capacity and symptoms. The regulatory decision was supported by findings from the double-blind, randomised Phase III SCOUT-HCM trial, which assessed the The post Bristol Myers Squibb secures expanded US approval for Camzyos appeared first on Pharmaceutical Business review....

Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates. BioMarin will screen and evaluate the computational outputs to The post BioMarin and Profluent partner on AI-designed enzyme therapies appeared first on Pharmaceutical Business review....

The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario. It is designed to help post-seed health science enterprises secure The post OBIO marks $704m funding milestone for Canadian health tech ventures appeared first on Pharmaceutical Business review....

Under the terms of the transaction, Knight Therapeutics will oversee regulatory submissions and commercial distribution of the therapy across Brazil, Argentina, Mexico, and Colombia. The agreement grants Knight The post Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab appeared first on Pharmaceutical Business review....

The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma retains marketing rights within Japan. The terms also include equity consideration and tiered royalties on The post Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma appeared first on Pharmaceutical Business review....

Under the transaction, AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. This will provide an estimated 12% stake in the The post AstraZeneca to invest $2bn in Summit for ADC combination therapies appeared first on Pharmaceutical Business review....

The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that The post Daiichi Sankyo, MSD withdraw cancer drug application appeared first on Pharmaceutical Business review....

The medication aims to reduce the volume of heterotopic ossification (HO) in these individuals and is administered orally at a recommended dose of 100mg once daily. Developed by The post Mirum and Incyte's Atebrioz approved for FOP in US appeared first on Pharmaceutical Business review....

The preclinical T-cell engagers will be developed using Amberstone's Tumor Microenvironment Activated ThErapeutics (T-MATE) platform. Henlius will select up to two targets under the agreement. The company will The post Amberstone and Henlius agree to develop solid-tumour T-cell engagers appeared first on Pharmaceutical Business review....

This treatment is approved for use alongside diet and exercise to improve blood sugar control. Onswik is intended to provide steady basal insulin levels for seven days. The The post FDA approves Lilly's Onswik for type 2 diabetes in adults appeared first on Pharmaceutical Business review....

The companies will integrate the Genialis Supermodel with Inventia's RASTRUM 3D cell model platform to study pancreatic ductal adenocarcinoma (PDAC) and test therapeutic hypotheses. Initial findings from the The post Genialis and Inventia to enhance pancreatic cancer treatment testing appeared first on Pharmaceutical Business review....

S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, The post Basecamp Research secures $140m for AI-driven therapies appeared first on Pharmaceutical Business review....

The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The The post BoomRay and Novartis Pharma sign $900m deal for radioligand therapy appeared first on Pharmaceutical Business review....

Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation, The post Boehringer and Envisagenics to develop precision cancer therapies appeared first on Pharmaceutical Business review....

The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial The post Made Scientific acquires cell therapy facility in Pennsylvania, US appeared first on Pharmaceutical Business review....

The authorisation allows both treatments to be used for patients with primary hypercholesterolaemia, including those with heterozygous familial and non-familial forms or mixed dyslipidaemia. This is said to The post EC approves Menarini and NewAmsterdam's obicetrapib therapies appeared first on Pharmaceutical Business review....

The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales milestones. The The post Telix to acquire ITM in deal worth up to $2.35bn appeared first on Pharmaceutical Business review....

The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has estimated global The post Sandoz and mAbxience agree on emicizumab biosimilar partnership appeared first on Pharmaceutical Business review....

The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with The post Ona Therapeutics to develop ADC with WuXi's payload-linker platform appeared first on Pharmaceutical Business review....

Under this arrangement, Dualitas will use its DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 new bispecific combinations. The company is set to receive $36.5m in The post Roche agrees $1bn deal with Dualitas for bispecific antibody research appeared first on Pharmaceutical Business review....